https://www.selleckchem.com/pr....oducts/bos172722.htm
More studies on the separate and/or cumulative role of both processes are warranted to suggest specific treatment options. Fenofibrate (FN is a commonly used hypolipidemic agent. However, the oral bioavailability of FNB is limited by slow dissolution due to its low solubility. Thus, investigations on novel FNB formulations are necessary for their use. To enhance the oral bioavailability of FNB using optimized Nanostructured Lipid Carrier (NLC) formulations. Hot homogenization followed by ultrasonication was used to prepare FNB-NLCs.
Like
Comment
Share
